Roivant and Priovant Therapeutics announced positive results from a phase 3 study of brepocitinib. The drug could have blockbuster potential in treating rare and orphan autoimmune diseases. 10 stocks ...

Immunovant develops monoclonal antibody therapeutics, with batoclimab as its lead candidate targeting autoimmune diseases such as myasthenia gravis, thyroid eye disease, and warm autoimmune hemolytic ...

Roivant financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to ...

Roivant Sciences (ROIV) traded sharply higher after its subsidiary Immunovant (IMVT) posted initial results from a Phase 2 trial evaluating its lead asset IMVT-1402 in rheumatoid arthritis, an ...

Tuesday's raiser was Leerink Partners prognosticator David Risinger. Well before market open, he added $1 to his Roivant price target for a new level of $18 per share. In doing so, he maintained his ...

Roivant Sciences (NASDAQ:ROIV) is gearing up to announce its quarterly earnings on Friday, 2026-02-06. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its ...

Vivek Ramaswamy, a former presidential candidate, is expected to announce his campaign for Ohio governor in 2026. In 2014 Ramaswamy co-founded Roivant Sciences, which buys or licenses promising drugs ...

View Roivant Sciences Ltd. ROIV stock quote prices, financial information, real-time forecasts, and company news from CNN.

Shares of Roivant Sciences (NASDAQ: ROIV) are soaring 11.4% higher as of 11:19 a.m. ET on Wednesday. The big gain came after Roivant and Priovant Therapeutics announced positive results from a ...